Search
Sarepta Therapeutics Inc
SRPTAdd to Watchlist
20.720USD
-0.200-0.96%
Close 09-15 16:00（ET）
2.19BMarket Cap
33.27P/E TTM
Sarepta Therapeutics Inc (SRPT) Stock Price Target & Forecast
Analyst Rating
Based on 27 analysts giving stock ratings to Sarepta Therapeutics Inc in the past month.
Hold
6 Strong Buy
3 Buy
12 Hold
5 Sell
1 Strong Sell
Target Price
22.509USD+10.07%
SRPT Analyst Recommendation Trends
In the current month, SRPT has received 3 Buy Ratings, 12 Hold Ratings, and 5 Sell Ratings. SRPT average Analyst price target in the last month is 22.509.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
6
6
5
5
5
5
4
4
3
3
3
3
3
3
3
3
12
12
14
14
14
14
14
15
1
1
1
1
1
1
1
1
5
5
5
4
4
4
4
4
27
27
28
27
27
27
26
27
SRPT Analyst Rating for Peer Comparison
Updated: Sep 15, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Biogen Inc
BIIB
7
17
12
1
0
37
Amgen Inc
AMGN
4
12
18
2
1
37
Eli Lilly and Co
LLY
10
17
6
1
0
34
AbbVie Inc
ABBV
8
19
6
0
0
33
Pfizer Inc
PFE
5
6
19
1
1
32
Merck & Co Inc
MRK
8
14
10
0
0
32
Vertex Pharmaceuticals Inc
VRTX
9
16
5
0
1
31
Gilead Sciences Inc
GILD
7
18
6
0
0
31
Regeneron Pharmaceuticals Inc
REGN
6
14
10
0
0
30
Alnylam Pharmaceuticals Inc
ALNY
5
18
7
0
0
30
Financial Forecasting
Based on analysts' estimates, SRPT EPS is projected to reach 0.140 in FY2026Q3, following reported EPS of -0.046 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-1.23
0.99
0.26
0.14
0.02
Actual
-2.70
3.15
-0.05
--
--
Surprise
-119.19%
+217.81%
-118.02%
--
--
FAQs
What is Sarepta Therapeutics Inc's expected revenue for the next quarter?
Sarepta Therapeutics Inc's expected revenue is 354.40M.
What is Sarepta Therapeutics Inc's price target?
Analysts forecast that Sarepta Therapeutics Inc's price target is USD 22.51, with the highest forecast at USD 38.00 and the lowest forecast at USD 5.00.
How have Sarepta Therapeutics IncSRPT's recent earnings per share performed?
The market expectation was USD -0.05, while Sarepta Therapeutics IncSRPT's earnings per share (EPS) for the previous quarter was USD 3.15. EPS for the next quarter is expected at USD 0.14.
What is the analyst rating for Sarepta Therapeutics Inc?
Based on the ratings of Sarepta Therapeutics Inc's stock from 27 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.